TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.
Advanced Malignant Neoplasm
DRUG: TQB2928 injection|DRUG: Penpulimab
Dose limiting toxicity (DLT), The relevant adverse reactions occurred within the first cycle, Baseline up to 3 weeks|Adverse event rate, The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)., Baseline up to 96 weeks
Objective response rate (ORR), Percentage of participants achieve complete response and partial response, Baseline up to 96 weeks|Complete response rate (CRR), Percentage of participants achieve complete response, Baseline up to 96 weeks|Disease Control Rate, It is the proportion of patients whose tumors have shrunk or stabilized for a certain amount of time and includes complete response (CR), partial response (PR), and stable (SD) cases, Baseline up to 96 weeks|Duration of Response, The time when the participants first achieved CR or PR to disease progression or death from any cause, Baseline up to 96 weeks|Progression-free Survival, The period between the beginning of treatment and the observation of disease progression or death from any cause in a patient with a tumor disease, Baseline up to 96 weeks|Overall survival (OS), From the first injection to the time of death from any cause., Baseline up to 96 weeks|Incidence of Anti-Drug antibody, The incidence of anti-drug antibody after administration of TQB2928 injection and penpulimab, Cycle 1 day 1, Cycle 5 day 1, and 28 days, 90 days after the last administration. (Each cycle 21 days)|Incidence of neutralizing antibodies, The incidence of neutralizing antibodies after administration of TQB2928 injection and penpulimab, Cycle 1 day 1, Cycle 5 day 1, and 28 days, 90 days after the last administration. (Each cycle 21 days)|Peak time (Tmax), The time to peak concentration, Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.|Peak concentration (Cmax), Maximum plasma drug concentration, Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.|The area under the plasma concentration time curve from zero to after 24h (AUC0-24h), Area under the plasma concentration time curve from zero to after 24h for TQB2928., Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.|Steady-state apparent volume of distribution (Vz/F), The total volume of body fluid required by the measured plasma drug concentration after the total amount of drug in the body is to be balanced., Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.|Minimum plasma concentration at steady state (Cmin,ss), The minimum plasma concentration after stabilization, Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.|Receptor Occupancy (RO%), The extent to which antibody drugs occupy cell surface targets, day 1 and day 8 of Cycle 1, day 1 and day 15 of Cycle 2, 28 days after the last administration. (each cycle 21 days)
This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.